New drug for chronic angina approved
Ranolazine extended-release tablets (Ranexa, CV Therapeutics) have received FDA approval for the treatment of chronic angina. Ranolazine prolongs the QT interval and should be reserved for patients who have not achieved an adequate response with other antianginal drugs.
New drug for chronic angina approved
Ranolazine extended-release tablets (Ranexa, CV Therapeutics) have received FDA approval for the treatment of chronic angina. Ranolazine prolongs the QT interval and should be reserved for patients who have not achieved an adequate response with other antianginal drugs. The exact mechanism of action is unknown, but the drug has antianginal and anti-ischemic effects that do not depend on reductions in heart rate or blood pressure. According to the company, ranolazine should be used in combination with amlodipine, beta-blockers, or nitrates and its effect on angina rate or exercise tolerance appears to be smaller in women than in men. Ranolazine is available as 500-mg extended-release tablets in bottles of 60 and 500.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
How Differences in Bispecific Therapies Impact Myeloma Treatment Operations
April 18th 2024According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.
